In a patient with an aortic graft infection treated with partial excision of the graft and negative intraoperative cultures, what intravenous antibiotic regimen is recommended, and do guidelines advise chronic oral suppressive antibiotic therapy, including the preferred agents?

Antibiotic Management for Culture-Negative Aortic Graft Infection After Partial Excision

For culture-negative aortic graft infection treated with partial excision, initiate 6 weeks of broad-spectrum intravenous antibiotics covering Gram-positive organisms (including MRSA) and Gram-negative bacteria, followed by chronic oral suppressive therapy that should be strongly considered as lifelong given the partial graft retention and high risk of recurrence. 1

Initial Intravenous Antibiotic Therapy (6 Weeks)

Since intraoperative cultures are negative but infection is clinically evident, empiric broad-spectrum coverage is essential:

• Vancomycin (for MRSA and methicillin-sensitive Staphylococcus aureus)
• Plus a beta-lactam or fluoroquinolone (for Gram-negative coverage including Pseudomonas)

The 6-week parenteral course is the standard recommendation from the American Heart Association guidelines for intra-abdominal vascular graft infections 1. In some cases, oral antibiotics with reasonable bioavailability can substitute for IV therapy during this period, but this requires infectious disease consultation 1.

Chronic Suppressive Antibiotic Therapy: Strongly Recommended

Lifelong suppressive antimicrobial therapy should be strongly considered in your patient because partial graft excision leaves residual prosthetic material in situ, which creates a persistent nidus for infection 1.

Who Needs Lifelong Suppression?

The AHA guidelines specifically identify patients most likely to benefit from lifelong suppression 1:

• Patients with in situ reconstruction using rifampin-bonded synthetic grafts
• Patients with in situ reconstruction (arterial or venous grafts) AND extensive perigraft infection
• Infection caused by MRSA, Pseudomonas, or multidrug-resistant organisms
• Patients who cannot tolerate extensive reconstructive surgery (high morbidity/mortality risk) 1

Your patient with partial excision falls into this high-risk category because residual graft material remains, creating ongoing infection risk.

Duration of Suppressive Therapy

After the initial 6-week IV course 1:

1. Additional 3-6 months of oral antibiotics should be administered to all patients
2. Then transition to lifelong suppressive therapy for high-risk patients (which includes partial excision cases)

The decision should be guided by:

• Persistently elevated inflammatory markers (ESR, CRP) 1
• Type of residual graft material
• Patient's ability to tolerate another major surgery if reinfection occurs

Antibiotic Choice for Culture-Negative Cases

For culture-negative infections with lifelong suppression, the preferred oral regimen should provide anti-staphylococcal coverage (since Gram-positive organisms, particularly S. aureus, cause the majority of aortic graft infections) 2:

Recommended Oral Suppressive Agents:

• First-line: Trimethoprim-sulfamethoxazole (excellent bioavailability, anti-staphylococcal including some MRSA coverage)
• Alternative: Doxycycline or minocycline (good bioavailability, broad coverage)
• For confirmed MRSA or high suspicion: Linezolid (though long-term use requires monitoring for toxicity)
• Fluoroquinolones (levofloxacin or ciprofloxacin) can be added if Gram-negative coverage is needed

Important Caveat:

If no effective or safe oral agent is available, intravenous antimicrobial suppression 2-3 times weekly should be considered 1. This is feasible through OPAT (outpatient parenteral antimicrobial therapy) programs 3.

Clinical Evidence Supporting Chronic Suppression

Multiple studies demonstrate that chronic suppressive therapy can achieve long-term survival in patients who cannot undergo complete graft excision:

• A 2000 study showed median survival of 32 months (up to 6 years) with indefinite suppressive therapy in patients too ill for definitive surgery 4
• A 2003 case series reported mean follow-up of 7.6 years without recurrent infection using aggressive drainage plus chronic suppression 5
• A 2021 OPAT study showed 8/11 patients alive at median 36 months, with 7/8 survivors on continuous oral suppression 3

Monitoring Strategy

Lifelong surveillance is mandatory 1:

• Monitor inflammatory markers (ESR, CRP) every 3-6 months initially
• Ultrasound or CT imaging every 3-6 months for 2 years, then every 6-12 months lifelong 1
• Clinical assessment for fever, pain, or signs of systemic infection

Critical Pitfalls to Avoid

1. Do not stop antibiotics after 6 weeks alone in partial excision cases—this is inadequate for residual prosthetic material 1

2. Do not use oral agents with poor bioavailability for suppression—ensure adequate tissue penetration and biofilm activity 2

3. Do not delay infectious disease consultation—these decisions require multidisciplinary input including vascular surgery, infectious disease, and microbiology 1

4. If the patient develops recurrent sepsis despite suppression, consider that oral therapy may be failing and IV suppression 2-3 times weekly may be necessary 1

5. For culture-negative cases, do not narrow coverage prematurely—maintain broad empiric coverage since the true pathogen is unknown

When Suppression May Not Be Feasible

If lifelong oral suppression is not technically feasible or proves ineffective, the guidelines state that intravenous chronic suppressive therapy 2-3 times weekly should be considered 1. This requires home health coordination but can be life-saving when oral options fail.